Long-Term Results of Intracardiac Mesenchymal Stem Cell Transplantation in Patients With Cardiomyopathy

Abstract

On the basis of experimental findings that mesenchymal stem cells (MSCs) can transdifferentiate into cardiomyocytes or endothelial cells under appropriate conditions, 9,10 we conducted a clinical study of cell therapy using autologous bone marrow-derived MSCs for patients with symptomatic HF on guideline-directed therapies. Here, we report the follow-up results up to 10 years after cell therapy using MSCs. Methods Study Design This study was a prospective, single-center, single-arm trial conducted at the National Cerebral and Cardiovascular Center in Suita, Japan. The institutional review board Editorial p 1446

Clinical application of mesenchymal stem cell in regenerative medicine: a narrative review

“…Increase in the LVEF NCT01291329 [ 107 ] AMI N/A 100 100 × 10 6 cell BMSC II No Improvement in cardiac function, induction of remodeling and regeneration, and improvement in quality of life NCT03047772 [ 108 ] HF I.V 30 1 × 10 6 /kg UC-MSC I/II No Reduction in ejection fraction. Improvements in left ventricular function, functional status, and quality of life NCT01739777 [ 109 ] HF N/A 8 1.2–6.5 × 10 7 cell BMSC N/A No There were no major differences in B-type natriuretic peptide, LVEF, and peak oxygen uptake at 2 months N/A [ 110 ] NIDCM TESI 34 N/A BMSC I/II No MSC therapy improves a variety of parameters in NIDCM irrespective of patient sex N/A [ 111 ] NIDCM TESI 37 10 × 10 7 cell BMSC I/II No Minnesota Living with Heart Failure Questionnaire score decreased. The Major Adverse Cardiac Event rate was lower in allo vs. auto.…”

“…In a study by Yagyu et al [ 110 ], 8 individuals with symptomatic heart failure were infused with BMSCs. During the follow-up period, no serious adverse events were observed.…”

Stem Cell-Based Therapy and Cell-Free Therapy as an Alternative Approach for Cardiac Regeneration

“…Transplanted stem cells electrochemical coupling must be homogenous with host CMCs. However, there is growing evidence showing no side effects related to arrhythmia after MSCs therapy [155,156]. A promising candidate for cardiac regenerative cell-based therapies are iPSCs (induced pluripotent stem cell), but SMCs may cause arrhythmia and they carry a risk of teratoma [157,158].…”